While EZH2 mutations have been described in approximately 2% of de novo acute leukemia [21], genomic loss of EZH2 can lead to epigenetic changes and overexpression of the HOX genes in myelodysplastic syndrome [22, 23]. This evidence concerns the gene EZH2 and acute leukemia.